Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Author:
Carmelo Carlo-Stella,Stephen Ansell,Pier Luigi Zinzani,John Radford,Kami Maddocks,Antonio Pinto,Graham P. Collins,Veronika Bachanova,Nancy Bartlett,Isabelle Bence-Bruckler,Mehdi Hamadani,Justin Kline,Jiri Mayer,Kerry J. Savage,Ranjana Advani et al.
Publication:
Clinical Lymphoma Myeloma and Leukemia
Copyright © 2022 Elsevier Inc. All rights reserved.